On November 3, EVEREST MED fell 5.05% in regular trading, trading at HK$25.6, with turnover of HK$65.13 million.
The main catalyst cited in public market information is continued digestion of a weaker broker stance, after UBS downgraded the stock to neutral and set a target price of RMB27, pressuring near-term risk appetite and the pace of valuation recovery.
Earlier positive fundamentals had included strong sales of Nefecon, first-half revenue of RMB1.148 billion, and a narrowing attributable net loss to RMB5.944 million, while another broker had previously upgraded the company to buy. More recently, the market focus shifted to the rating downgrade, outweighing support from commercialization progress and pipeline updates, including products spanning kidney disease, anti-infectives, and autoimmune diseases.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments